Mounjaro And Pregnancy: What You Need To Know - Guide | Cured Pharmacy

Mounjaro And Pregnancy: What You Need To Know

WEIGHT LOSS · 22 MIN READ
Written by Cured Pharmacy
Published on 19 August 2026
★★★★★ Judge.me Reviews
Mounjaro Weight Loss Injections (Tirzepatide) KwikPen

Featured Product

Mounjaro Weight Loss Injections (Tirzepatide) KwikPen

From£145.00£124.99 UK-based prescribers · Discreet delivery · Free private prescription
Start Assessment → ✓ Lowest price guarantee
DISCOUNT CODE: FIRST20

£20 off for new patients

Tarun Kumar, Prescribing Pharmacist at Cured Pharmacy

Medically reviewed by

Tarun Kumar, Prescribing Pharmacist (GPhC 2233073)

Last reviewed: 19 August 2026

If you are currently taking Mounjaro for weight loss and you are trying to conceive, already pregnant, or simply wondering what happens if you fall pregnant while on treatment, you are not alone. This is one of the most frequently asked questions among women using weight loss injections across the UK, and it deserves a genuinely thorough, honest answer. The concern is completely understandable: Mounjaro is a powerful medication, and pregnancy changes everything about how your body responds to drugs. In this guide, we cover every angle, from what the clinical data currently says, to what you should practically do if you discover you are pregnant mid-treatment, to how to protect yourself with the right contraception while on Mounjaro.

Summary

Mounjaro (tirzepatide) is not considered safe to use during pregnancy. Current guidance from the MHRA and the manufacturer recommends stopping treatment at least one month before attempting to conceive, and immediately if pregnancy is confirmed unexpectedly.

  • Mounjaro is contraindicated in pregnancy based on animal study data showing potential harm to the foetus.
  • Women of childbearing age must use effective contraception throughout Mounjaro treatment.
  • If you discover you are pregnant while on Mounjaro, stop treatment and contact your prescriber immediately.
  • Mounjaro may inadvertently improve fertility by supporting weight loss and regulating hormones, increasing the chance of unplanned pregnancy.
  • Cured Pharmacy provides structured clinical oversight and contraception advice as part of every Mounjaro weight loss consultation.

Table of Contents

  1. Why Mounjaro and Pregnancy Is Such an Important Topic Right Now
  2. What the Safety Data Actually Says About Tirzepatide in Pregnancy
  3. The Fertility Connection: Why Mounjaro Can Increase Your Chances of Conceiving
  4. Mounjaro and Pregnancy: What You Need to Know If You Fall Pregnant on Treatment
  5. Contraception While on Mounjaro: What Actually Works
  6. Planning a Pregnancy After Mounjaro: A Practical Timeline
  7. GLP-1 Medications and Pregnancy Safety Comparison Table
  8. Key Takeaways
  9. When to Seek Professional Advice
  10. Scientific References
  11. FAQs

Why Mounjaro and Pregnancy Is Such an Important Topic Right Now

Mounjaro (tirzepatide) has become one of the most prescribed weight loss medications in the UK since it received MHRA approval for chronic weight management in adults. Hundreds of thousands of women across England, Scotland, Wales, and Northern Ireland are now using it. Many of these women are in their reproductive years, and for good reason: obesity significantly affects fertility, menstrual regularity, and pregnancy outcomes. So it is inevitable that the question of what happens when Mounjaro meets pregnancy arises with increasing urgency.

In 2026, prescribers across the UK are seeing a pattern that no one fully anticipated at the time of the drug's launch. Because Mounjaro supports substantial weight loss, it frequently restores ovulation in women who had been experiencing irregular or absent periods due to obesity or polycystic ovary syndrome (PCOS). Women who believed they were unlikely to conceive naturally are falling pregnant. Some are on Mounjaro when it happens. This is not a scare story; it is simply a clinical reality that demands clear, practical information.

Mounjaro Pregnancy Risk Checker

Answer the questions below to understand your current pregnancy risk profile while on Mounjaro. This is for informational purposes only and does not replace clinical advice.

Understanding Mounjaro and Pregnancy: What You Need to Know is not just about risk avoidance. It is about empowering women to make informed decisions at every stage of their reproductive journey. Whether you are actively trying to lose weight before conceiving, unexpectedly pregnant, or somewhere in between, the guidance in this article is grounded in the most current clinical evidence available in the UK.

What the Safety Data Actually Says About Tirzepatide in Pregnancy

Let us be straightforward. There are no controlled clinical trials of tirzepatide in pregnant humans. This is not unusual; conducting drug trials in pregnant women raises serious ethical concerns, and most medications used widely in adults have limited or no direct human pregnancy data at the point of licensing. What we do have is animal study data, and that data raises enough concern for the regulatory bodies to recommend against using Mounjaro during pregnancy.

The European Medicines Agency (EMA) and the MHRA both reviewed reproductive toxicology studies conducted on rats and rabbits during tirzepatide's approval process. These studies showed adverse effects on foetal development at doses comparable to those used therapeutically in humans. Specifically, studies identified reduced foetal weight and skeletal abnormalities in offspring exposed to tirzepatide in utero. The manufacturer's Summary of Product Characteristics (SmPC) for Mounjaro explicitly states that the drug should not be used during pregnancy.

It is also worth understanding the mechanism. Tirzepatide acts on both GLP-1 and GIP receptors, which play roles in appetite regulation, glucose metabolism, and insulin secretion. GLP-1 receptors are also expressed in placental tissue. While the clinical significance of this in humans is not yet fully characterised, it is a biologically plausible pathway through which the drug could theoretically influence placental function. This adds to the rationale for caution.

  • Animal studies show foetal weight reduction and skeletal malformations with tirzepatide exposure during pregnancy.
  • GLP-1 receptors are expressed in human placental tissue, raising theoretical concerns about placental effects.
  • The MHRA and EMA both list pregnancy as a contraindication in Mounjaro's prescribing information.
  • No human pregnancy outcome data from controlled trials exists as of 2026.
  • Pregnancy registries are being established to collect real-world data over time, but results are not yet available.

If you are considering weight loss treatment and are of childbearing potential, any reputable prescriber should discuss this with you as part of the consultation process. At Cured Pharmacy, this happens every time, without exception.

Here is something many women are genuinely surprised to learn. Taking Mounjaro can make you more fertile, not less. This is one of the most practically important aspects of Mounjaro and pregnancy, and it is one that does not get nearly enough attention in mainstream guidance.

Obesity is strongly linked to ovulatory dysfunction. Women with a higher BMI frequently experience irregular periods, anovulation (cycles where no egg is released), and conditions like PCOS, all of which reduce natural fertility. When Mounjaro drives meaningful weight loss, it often restores ovulatory function. Women who had not had a regular period in years find that cycles return within a few months of starting treatment. This is genuinely positive news from a long-term health perspective, but it carries an important implication: if you were relying on absent or irregular periods as informal contraception, you may no longer be able to do so.

There is also an indirect hormonal dimension. Excess adipose (fat) tissue produces oestrogen, which at elevated levels can suppress ovulation by disrupting the hypothalamic-pituitary-ovarian axis. As body fat reduces on Mounjaro, oestrogen levels normalise, which can restore regular ovulation. Additionally, tirzepatide's GIP receptor action may have direct effects on reproductive hormones, though this area of research is still emerging.

  • Weight loss of even 5 to 10 percent of body weight can restore ovulation in women with obesity-related anovulation.
  • PCOS-related infertility frequently improves with weight reduction, and Mounjaro drives substantial loss.
  • Women who have had absent periods may experience cycle restoration within weeks of starting Mounjaro.
  • Do not assume absent or irregular periods make pregnancy impossible while on Mounjaro.

This is why the fertility conversation is not optional. If you are a woman of reproductive age starting Mounjaro, the question "what contraception do you use?" must be part of the initial assessment. For those who want to explore the broader context of women's health support during and after weight loss treatment, Vitabiotics Wellwoman Original is a well-regarded nutritional support option to discuss with your prescriber as you transition through different phases of treatment.

Mounjaro and Pregnancy: What You Need to Know If You Fall Pregnant on Treatment

So what actually happens if you discover you are pregnant while taking Mounjaro? First, do not panic. One inadvertent injection is unlikely to cause immediate harm, but the most important thing to do is stop treatment straight away and contact your prescriber or GP as soon as possible. Do not continue Mounjaro because you are worried about weight regain or appetite returning. Foetal safety takes precedence, full stop.

Your prescriber will likely advise you to report the pregnancy to the manufacturer's pharmacovigilance team. Eli Lilly, who manufactures Mounjaro, operates a pregnancy exposure registry specifically to collect data on outcomes when tirzepatide has been used inadvertently during pregnancy. Reporting your case helps build the evidence base for future clinical guidance and does not involve any additional treatment or commitment on your part. It is simply a contribution to collective knowledge.

Once you have stopped Mounjaro, your care moves into standard antenatal channels. You will be offered booking appointments with your midwife, and if you have underlying conditions such as type 2 diabetes or pre-existing obesity, you may be referred to a specialist obstetric team. Women with a BMI over 35 are typically managed in consultant-led antenatal care in the UK, which provides additional monitoring and support throughout pregnancy.

  • Stop Mounjaro immediately upon confirmed pregnancy and contact your prescriber the same day.
  • Report inadvertent pregnancy exposure to Eli Lilly's pharmacovigilance registry.
  • Transition promptly into NHS antenatal care via your GP or midwife.
  • Women with obesity or type 2 diabetes should expect consultant-led obstetric care.
  • Do not restart Mounjaro until after birth and once breastfeeding has concluded (or you have made a decision not to breastfeed).

Weight management during pregnancy is best supported through a dietitian-led approach, with a focus on appropriate gestational weight gain rather than active weight loss. The NICE guideline on weight management before, during, and after pregnancy (NG150) is a valuable reference point for both patients and clinicians navigating this period. After pregnancy, when the time is right, treatments like Wegovy (semaglutide) or Mounjaro can be reconsidered under proper clinical supervision.

Contraception While on Mounjaro: What Actually Works

This is where things get nuanced, and where many women are caught off guard. The standard advice from Mounjaro's SmPC is that women of childbearing potential should use effective contraception during treatment and for at least one month after stopping. But there is a critical caveat that many prescribers do not make explicit enough.

Oral contraceptive pills may be less reliable while on Mounjaro. Here is why. Mounjaro slows gastric emptying, meaning food and medications take longer to leave the stomach and enter the small intestine where absorption occurs. Combined oral contraceptives rely on consistent absorption to maintain adequate blood levels of the hormones. If gastric emptying is significantly slowed, the timing and completeness of pill absorption may be affected, potentially reducing contraceptive efficacy.

The SmPC for Mounjaro specifically flags this for the first four weeks of treatment and when doses are escalated, as these are the periods when the gastric emptying effect is most pronounced. Women who rely solely on oral contraceptive pills are advised to add a barrier method (such as condoms) during these windows. Long-acting reversible contraceptives (LARCs), which are not absorbed orally and are not affected by gastric emptying at all, are generally considered the most reliable option for women on Mounjaro.

  • Hormonal oral pills may have reduced absorption due to Mounjaro's effect on gastric emptying.
  • Barrier methods should be added during the first four weeks of treatment and any dose escalation period.
  • LARCs (implants, intrauterine devices, hormonal coils) are unaffected by gastric emptying and are the most reliable choice.
  • Injectable contraceptives and transdermal patches are also generally considered reliable as they bypass the gut.
  • Discuss your specific contraceptive method with your prescriber at the start of Mounjaro treatment, not after.

At Cured Pharmacy, every woman starting Mounjaro is asked about contraception as part of the clinical assessment process. If there is any uncertainty, the prescriber will address it directly. This is the kind of structured, thoughtful oversight that distinguishes a proper clinical weight loss service from simply dispensing medication. You can use discount code FIRST20 to get £20 off your first Mounjaro order at Cured Pharmacy if you are a new patient.

Planning a Pregnancy After Mounjaro: A Practical Timeline

If you are currently on Mounjaro and hoping to conceive in the future, the good news is that with proper planning, you can use the treatment period to get your body into the best possible condition for a healthy pregnancy. The key is to plan the transition carefully, rather than stopping abruptly or continuing until the last moment.

The SmPC recommends stopping Mounjaro at least one month before attempting to conceive. This allows the drug to clear from your system. Tirzepatide has a half-life of approximately five days, meaning that after around four to five weeks, circulating drug levels will be negligible. The one-month buffer is a pragmatic and cautious recommendation that aligns with the pharmacokinetics.

However, from a practical standpoint, stopping further in advance may be advisable, particularly if you have been on higher doses (10mg or 15mg). The reason is not purely pharmacological; it is also about stabilising your weight and nutritional intake before conception. Rapid weight loss, even when intentional and medically supervised, can affect micronutrient levels. Iron, folate, vitamin D, and vitamin B12 are particularly worth monitoring before trying to conceive. You may wish to speak with your prescriber about a comprehensive nutritional review as part of your pre-conception care.

  • Stop Mounjaro at least one month before trying to conceive, as recommended in the SmPC.
  • Consider stopping further in advance if on higher doses to allow weight and nutrition to stabilise.
  • Begin a quality folic acid supplement (400mcg daily, or 5mg if high risk) ideally three months before trying to conceive.
  • Have nutritional blood tests (iron, vitamin D, folate, B12) before conception to identify and address any deficiencies.
  • Discuss with your GP or prescriber whether any of the weight-related improvements Mounjaro achieved (such as improved blood glucose control) require alternative management once the drug is stopped.

For nutritional support in the pre-conception and early pregnancy window, consider a comprehensive women's supplement. Vitabiotics Perfectil Plus and Vitabiotics Ultra Magnesium are available at Cured Pharmacy and may support overall nutritional status during this transitional period, though always discuss supplementation with a healthcare professional before starting.

GLP-1 Medications and Pregnancy Safety: Comparison Table

Medication Class Pregnancy Category (UK/EMA) Animal Study Findings MHRA/SmPC Recommendation Washout Before Conception
Mounjaro (Tirzepatide) GLP-1/GIP dual agonist Contraindicated Foetal weight reduction, skeletal abnormalities in rats and rabbits Do not use during pregnancy; stop at least 1 month before conception Minimum 1 month (approx. 5 half-lives)
Wegovy / Ozempic (Semaglutide) GLP-1 receptor agonist Contraindicated Structural malformations, embryonic death in rodent studies Do not use during pregnancy; stop at least 2 months before conception Minimum 2 months (longer half-life ~1 week)
Liraglutide (Saxenda/Victoza) GLP-1 receptor agonist Contraindicated Foetal and neonatal mortality and malformations in animal studies Do not use during pregnancy; stop when pregnancy confirmed Minimum 2–3 weeks (half-life ~13 hours)
Orlistat (Alli/Xenical) Lipase inhibitor Not recommended No evidence of direct foetal harm in animals Not recommended during pregnancy; stop if pregnancy occurs No specific washout required
Metformin (used in obesity/PCOS) Biguanide Can be used with caution No teratogenicity in animal studies Can be continued with specialist guidance in T2DM/PCOS during pregnancy No washout typically required

It is worth noting that semaglutide (the active ingredient in Wegovy) has a significantly longer half-life than tirzepatide, which is why the washout period before attempting conception is longer at two months. This is an important practical difference when switching between treatments or planning conception after either drug.

Key Takeaways

  • Mounjaro is contraindicated during pregnancy; animal studies show foetal harm and regulatory guidance is unambiguous.
  • Mounjaro can restore fertility in women with obesity-related anovulation or PCOS, making effective contraception essential throughout treatment.
  • Oral contraceptive pills may be less reliable due to Mounjaro's effect on gastric emptying; LARCs are the most dependable option.
  • If you fall pregnant while on Mounjaro, stop treatment immediately and contact your prescriber; report to Eli Lilly's pregnancy registry if advised.
  • Plan conception at least one month after stopping Mounjaro, with nutritional review and folic acid supplementation in place beforehand.

When to Seek Professional Advice

You should contact your prescriber or GP without delay in any of the following situations:

  • You have discovered you are pregnant while currently taking Mounjaro.
  • Your periods have returned or become regular since starting Mounjaro and you are not using adequate contraception.
  • You are planning to try for a baby within the next six months and want to plan your transition off Mounjaro safely.
  • You are unsure whether your current contraceptive method is compatible with Mounjaro treatment.
  • You have conditions such as PCOS, type 2 diabetes, or a history of gestational diabetes that need to be factored into both your weight loss and pregnancy planning.
  • You are considering starting Mounjaro but are also trying to conceive or planning to do so in the near future.

Cured Pharmacy provides access to UK-based prescribers who are experienced in weight loss medicine and who take women's reproductive health seriously as part of the consultation process. Every assessment includes a review of your contraception status, medical history, and any upcoming life plans that might affect the suitability and timing of treatment. If you are considering starting Mounjaro and want to do so with proper clinical support, explore weight loss treatment options at Cured Pharmacy. New patients can use code FIRST20 for £20 off their first order.

Scientific References

  1. Mounjaro (tirzepatide) Summary of Product Characteristics, Eli Lilly and Company Ltd, 2023, via Electronic Medicines Compendium (EMC) [Accessed 19 August 2026]
  2. NICE Technology Appraisal TA1026: Tirzepatide for managing overweight and obesity, National Institute for Health and Care Excellence, 2024 [Accessed 19 August 2026]
  3. NICE Guideline NG150: Weight management before, during and after pregnancy, National Institute for Health and Care Excellence, 2021 [Accessed 19 August 2026]
  4. MHRA: Mounjaro tirzepatide regulatory information and guidance, Medicines and Healthcare products Regulatory Agency, 2023 [Accessed 19 August 2026]
  5. EMA European Public Assessment Report (EPAR) for Mounjaro (tirzepatide), European Medicines Agency, 2023 [Accessed 19 August 2026]
  6. Jastreboff AM et al., Tirzepatide Once Weekly for the Treatment of Obesity, New England Journal of Medicine, 2022 [Accessed 19 August 2026]
  7. Frías JP et al., Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes, The Lancet, 2022 [Accessed 19 August 2026]
  8. NHS: Polycystic ovary syndrome (PCOS) treatment, National Health Service, 2023 [Accessed 19 August 2026]
  9. Royal College of Obstetricians and Gynaecologists: Care of Women with Obesity in Pregnancy, Green-top Guideline No. 72, RCOG, 2018 [Accessed 19 August 2026]
  10. Diabetes UK: Pregnancy and diabetes guidance, Diabetes UK, 2024 [Accessed 19 August 2026]
  11. British National Formulary (BNF): Tirzepatide monograph, NICE/BNF, 2024 [Accessed 19 August 2026]
  12. Cena H et al., Obesity, Polycystic Ovary Syndrome and Infertility: A New Avenue for GLP-1 Receptor Agonists, Journal of Clinical Medicine, 2020 [Accessed 19 August 2026]
  13. NHS: Planning your pregnancy, National Health Service, 2023 [Accessed 19 August 2026]
  14. MHRA Drug Safety Update: GLP-1 receptor agonists — known risks and monitoring requirements, Medicines and Healthcare products Regulatory Agency, 2024 [Accessed 19 August 2026]
  15. Faculty of Sexual and Reproductive Healthcare (FSRH): Drug Interactions with Hormonal Contraception, FSRH, 2022 [Accessed 19 August 2026]
  16. Melo AS et al., GLP-1 receptor agonists and female reproductive health: emerging evidence and clinical implications, Frontiers in Endocrinology, 2023 [Accessed 19 August 2026]

Start Your Assessment For Weight Loss

Start your journey to better health today.

  • Reviewed by UK-based prescribers
  • Takes under 3 minutes
  • Discreet Packaging

Start Your Journey To Better Health Today.

Once you complete a short online assessment, you will be able to choose your preferred treatment and quantity from a list of safe, medically approved options tailored to you.

Start My AssessmentReturning Customer?Log In to Your Account

Frequently Asked Questions

Can you take Mounjaro while pregnant?
Taking Mounjaro while pregnant is not recommended and is listed as a contraindication in its official prescribing information. Animal studies have shown potential foetal harm with tirzepatide exposure during pregnancy, and no safe threshold for human use has been established. If pregnancy occurs during treatment, Mounjaro should be stopped immediately and a prescriber contacted without delay.

How long should you stop Mounjaro before trying to conceive?
You should stop Mounjaro at least one month before attempting to conceive, as recommended in the official Summary of Product Characteristics. This allows tirzepatide to clear from your system, given its five-day half-life. Some clinicians advise stopping earlier to allow weight and nutritional status to stabilise before conception, which may improve pregnancy outcomes overall.

Is it safe to rely on the contraceptive pill while on Mounjaro?
Relying solely on the oral contraceptive pill while on Mounjaro may not be fully reliable, as Mounjaro slows gastric emptying, which can affect pill absorption during the first four weeks of treatment and after each dose increase. The FSRH and Mounjaro's SmPC both advise adding barrier contraception during these windows, or switching to a long-acting reversible contraceptive method to ensure reliable protection.

What should you do if you fall pregnant while on Mounjaro?
If you fall pregnant while on Mounjaro, you should stop treatment immediately and contact your GP or prescriber the same day. Mounjaro and pregnancy exposure should ideally be reported to Eli Lilly's pharmacovigilance registry to contribute to safety data. You should then transition into standard NHS antenatal care, where any underlying health conditions such as obesity or type 2 diabetes will receive appropriate specialist management.

Back to blog